Cyclosporin and Sulfasalazine Combination in the Treatment of Early Rheumatoid Arthritis

References

• Pincus T, Marcum SB, Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology provate practices: II. Second-line drugs and prednisolone. J Rheuma-tol 1992;19:1885–94.
   Google Scholar
• Pincus T. Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988;41:1037–41.
   PubMed Web of Science ®Google Scholar
• Reilly PA, Cosh JA, Maddison PJ, Rasker JJ, Silman AL. Mortality and survival in rheumatoid arthritis: a 25-yr prospective study of 100 patients. Ann Rheum Dis 1990;49: 363–9.
   Google Scholar
• Pincus TS. Is mortality increased in rheumatoid arthritis? J Musculoskeletal Med 1988;5:27–46.
   Google Scholar
• Ryffel B. Pharmacology of cyclosporin. VI. Cellular activa-tion: regulation of intracellular events by cyclosporin. Pharmacol Rec 1989;41:407–22.
   Google Scholar
• Rijthoven AWAM van, Dijkmans BAC, Goei The HS, Hermans J, Montor-Beckers ZLMB, Jacobs PCJ, et al. Cyclosporin treatment for rheumatoid arthritis: a placebo-controlled double-blind multicentre study. Ann Rheum Dis 1986;45:726–31.
   Google Scholar
• Form O, Bjerkhoel F, Salvesen CF, et al. An open, controlled randomized comparison of cyclosporin and azathioprin in the treatment of arthritis: a preliminary report. Arthritis Rheum. 1987;30:88–92.
   Google Scholar
• Dougados M, Awada H, Amor B. Cyclosporin in rheumatoid arthritis: a double-blind, placebo-controlled study in 52 patients. Ann Rheum Dis 1988;47: 127–33.
   Google Scholar
• Yocum DE, Klipper JH, Wilder RL, Gerber NL, Austin HA, Wahl SM, et al. Cyclosporin A in severe treatment-refractory rheumatoid arthritis. Ann Int Med 1988;109:863–9.
   PubMed Web of Science ®Google Scholar
• Dougados M, Luchesne L, Awada H, et al. Assessment of efficiency and acceptability of low dose cyclosporin in patients with rheumatoid arthritis. Ann Rheum Dis 1989;48:550–6.
   PubMed Web of Science ®Google Scholar
• Tugwell P, Bombardier C, Gent M, Bennett KJ, Bensen WG, Carette S, et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990;335:1051–5.
   PubMed Web of Science ®Google Scholar
• Ferraccioli GF, Della Casa Alberighi O, Marubini E, Priolo F, Mathieu A, Fantini F, et al. Is the control of disease progression within our grasp? Review of the GRISAR study. (Gruppo Reumatologi Italiani Studio Artrite Reumatoide). Br J Rheumatol. 1996;35 Suppl 2:8–13.
   Google Scholar
• Ferraccioli GF, Bambara LM, Ferraris M, Perpignano G, Cattaneo R, Porzio F, et al. Effects of cyclosporin on joint damage in rheumatoid arthritis. The Italian Rheumatologists Study Group on Rheumatoid Arthritis. Clin Exp Rheumatol. 1997;15 Suppl 17:S83–9.
   Google Scholar
• An International Consensus Report: The use of cyclosporin A in rheumatoid arthritis Br J Rheumatol 1993;32 Suppl. 1: 1–3.
   Google Scholar
• Panayi GS, Tugwell P. The use of cyclosporin A microemul-sion in rheumatoid arthritis: conclusions of an international review. Br J Rheumatol 1997;36:808–11.
   Google Scholar
• Pullar T, Hunter JA, Cappell HA. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulpha-salazine with placebo and sodium aurothiomalate. Br Med J 1983;287:1102–4.
   Google Scholar
• Hannonen P, Mottonen T, Hakola M, Oka M. Sulphasalazine in early rheumatoid arthritis: A 48 week double-blind prospective, placebo-controlled study. Arthritis Rheum 1993;36:1501–9.
   PubMed Web of Science ®Google Scholar
• Box SA, Pullar T. Sulphasalazine in the treatment of rheumatoid arthritis. Br J Rheumatol 1997;36:382–6.
   PubMedGoogle Scholar
• Kanerud L, Scheynius A, Hafstrom I. Evidence of a local intestinal immunomodularoty effect of sulphasalazine in rheumatoid arthritis. Arthritis Rheum 1994;37:1138–45.
   Google Scholar
• Klippel JH. Winning the battle, losing the war? Another editorial about rheumatoid arthritis. J Rheumatol 1990;17:1118–22.
   PubMed Web of Science ®Google Scholar
• Paulus HE. The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis. Arthritis Rheum 1990;33:113–20.
   PubMed Web of Science ®Google Scholar
• Haagsma CJ, van Riel PL. Combination of second-line antirheumatic drugs. Ann Med. 1997;29:169–73.
   Web of Science ®Google Scholar
• Yocum DE. Combination therapy with cyclosporin in rheumatoid arthritis. Br J Rheumatol 1996;35 Suppl 2:19–23.
   Google Scholar
• Strand V. The future use of biologic therapies in combination for the treatment of rheumatoid arthritis. J Rheumatol 1996;23 Suppl 44:91–6.
   Google Scholar
• Choy EH, Scott DL. Drug treatment of rheumatic diseases in the 1990s. Achievements and future developments. Drugs 1997;53:337–48.
   Google Scholar
• Landewé RBM, Dijkmans BAC, Woude van Breedveld FC, Mihatsch MJ, Bruijn JA. Longterm low dose cyclosporine in patients with rheumatoid arthritis: renal function loss without structural nephropathy. J Rheumatol 1996;23:61–4.
   Google Scholar
• Salaffi F, Carotti M, Cervini C. Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis. Scand J Rheumatol 1996;25:16–23.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Ritchie D, Boyle JA, McInnes JM, Grieveson P, Buchanan W. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med (N.S.) 1968;37:393–406.
   Google Scholar
• Lee P, Jasani MK, Dick WC, Buchanan WW. Evaluation of a functional index in rheumatoid arthritis. Scand J Rheumat 1973;2:71–7.
   PubMedGoogle Scholar
• Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982;9:789–93.
   Google Scholar
• Heijde DMFM van der, Hof MA van, Riel PLCM van, et al. Judging disease activity in clinical practice in rheumatoid erthritis. First step in the development of a 'disease activity score'. Ann Rheum Dis 1990;49:916–20.
   Google Scholar
• Gestel AM van, Prevoo MLL, Hof MA van't, Rijswijk MH van, de Putte LBA van, Riel PLCM van. Development and validation of the European Leage Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 1996;39:34–40.
   Google Scholar
• Larsen A. Radiological Grading of rheumatoid arthritis: an interobserver study. Scand J Rheumatol 1973;2:136–8.
   PubMedGoogle Scholar
• Heijde A van, Jakobs JWG, Bijlsma JWJ, Heurkens AHM, Booma-Frankfort C van, Veen MJ van, et al. The effective-ness of early treatment with "second-line" antirheumatic drugs. Randomised controlled trial. Ann Int Med 1996;124:699–707.
   Google Scholar
• Emery P. Early rheumatoid arthritis: therapeutic strategies. Scand J Rheumatol 1994;23 Suppl. 100:3–7.
   Google Scholar
• Forre O, Bjerkhoel F, Kjeldsen-Kragh J, Ostensen H, Astor T, Mae E, et al. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Arthritis Rheum 1994;37:1506–12.
   PubMed Web of Science ®Google Scholar
• Landewé RBM, Goei The HS, Rijthoven AWAM van, Breedveld FC, Dijkmans BAC. A randomized double-blind 24 weeks controlled study of low-dose cyclosporin versus chloroquine. Arthritis Rheum 1994;37: 637–43.
   Google Scholar
• Pasero G, Priolo F, Marubini E, Fantini F, Ferraccioli G, Magaro M, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996;39:1006— 15.
   Google Scholar
• Zeidler HK, Kvien TK, Hannonen P, Wollheim FA, Forre O, Geidel H, et al. Progression of joint damage in early active severe rheumatoid arthritis during 18 month of treatment: comparison of low-dose cyclosporin and parenteral gold. Br J Rheumatol 1998;37:874— 82.
   Google Scholar
• Flipo RM, Emery P, Scott DGI, Situnayake RD, Prowse PJ, James DW, et al. Safety and tolerability of conversion from stable Sandimmun® maintenance treatment to Sandimmun Neoral® in patients with rheumatoid arthritis. J Rheumatol 1998;25:1263–9.
   Google Scholar
• Svarty N. Salazopyrin, a new sulfanilamide preparation: a. therapeutic results in rheumatic polyarthritis; b. therapeutic results in ulcerative colitis; c. toxic manifestations in treatment with sulfanilamide preparations. Acta Med Scand 1942;110: 577 — 98.
   Google Scholar
• McConkey B, Amos RS, Butler EP. Salazopyrin in rheuma-toid arthritis. Agents Actions 1978;8:438— 41.
   Google Scholar
• Rains CP, Noble S, Faulds D. Sulfasalazine. A review ot its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 1995;50: 137— 56.
   Google Scholar
• Fuchs HA, Kaye JJ, Callahan LF, Nance P, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989;16: 585–91.
   Google Scholar
• Möttonen TT. Prediction of erosiveness and rate of develop-ment of new erosions in early rheumatoid arthritis. Ann Rheum Dis 1988;47:648–53.
   PubMed Web of Science ®Google Scholar
• Heijde DMFM van, Leeuwen MA van, Riel PLCM van, Koster AM, Hof MA van, Rijswijk MH van, et al. Biannual radiographic assessments of hands and feet in a three-year prospective follow-up of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35:26 —34.
   Google Scholar